Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Century Therapeutics, Inc. (IPSC)

Century Therapeutics appoints Joseph Truitt to board, expanding it to seven directors

Neutral Impact 2 of 5 leadership Written later

Century Therapeutics added Joseph Truitt, chief executive of iECURE, Inc., as a director effective September 9, 2026, increasing the board from six to seven members. Truitt will also serve on the Compensation Committee and receive standard non-employee director pay, including a stock option award and an annual cash retainer, so the appointment adds a board member with biotechnology executive experience.

Key points

  • Truitt appointed effective September 9, 2026 as a Class I director with a term expiring at the 2028 Annual Meeting of Stockholders
  • Board size increased from six to seven directors; Truitt will serve on the Compensation Committee
  • Initial option grant of 148,000 shares of common stock, vesting in equal monthly installments over 36 months, plus an annual cash retainer of $40,000
  • Board determined Truitt is independent under Nasdaq listing rules

The filing

CompanyCentury Therapeutics, Inc. (IPSC)
Form8-K, current report
Filed with the SECSep 9, 2026, 4:10 PM ET
Accession number0001104659-26-106312

Items reported: 5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 09, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.